Stockholders' Equity (Tables)
|
12 Months Ended |
Dec. 31, 2016 |
|---|
| Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
|
| Schedule of Share-based Compensation, Activity |
The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the years ended December 31, 2016, 2015 and 2014: | | | For the Years Ended December 31, | | | ($ in thousands) | | 2016 | | 2015 | | 2014 | | | Employee awards | | $ | 7,386 | | $ | 8,130 | | $ | 5,492 | | | Executive awards of Fortress Companies' stock | | | - | | | 2,228 | | | - | | | Non-employee awards | | | 33 | | | 33 | | | 54 | | | Fortress Companies (1), (2) | | | 4,709 | | | 3,900 | | | - | | | Total stock-based compensation expense | | $ | 12,128 | | $ | 14,291 | | $ | 5,546 | | | (1)
|
Consists of approximately $28,000 of Avenue's compensation expenses, approximately $3.9 million of Checkpoint's compensation expense, approximately $0.5 million of JMC's compensation expenses, approximately $0.3 million of Helocyte's compensation expenses, approximately $7,000 of Cellvation's compensation expenses and approximately $42,000 of National Holdings' compensation expenses on stock and option grants for the year ended December 31, 2016
| | (2) | Consists of approximately $50,400 of Avenue's compensation expenses, approximately $3.3 million of Checkpoint's compensation expense, and approximately $0.6 million of JMC's compensation expenses on stock grants for the year ended December 31, 2015. |
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable |
The following table summarizes Fortress stock option activities excluding activities related to Fortress Companies: | | | | | | | Total weighted | | Weighted average | | | | | | | Weighted average | | average intrinsic | | remaining contractual | | | | | Number of shares | | exercise price | | value | | life (years) | | | Options vested and expected to vest at December 31, 2015 | | | 1,779,365 | | $ | 4.37 | | $ | 666,396 | | | 6.32 | | | Forfeited | | | (648,864) | | | 0.51 | | | - | | | - | | | Options vested and expected to vest at December 31, 2016 | | | 1,130,501 | | $ | 3.73 | | $ | 602,451 | | | 4.93 | | | Exercisable as of December 31, 2016 | | | 1,105,501 | | $ | 3.71 | | $ | 602,451 | | | 4.91 | |
|
| Nonvested Restricted Stock Shares Activity |
The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies: | | | | | Weighted | | | | | | | average | | | | | Number of shares | | grant price | | | Unvested balance at December 31, 2015 | | | 8,757,935 | | $ | 2.47 | | | Restricted stock granted | | | 1,240,868 | | | 2.77 | | | Restricted stock cancelled | | | (33,333) | | | 2.69 | | | Restricted stock vested | | | (173,333) | | | 2.73 | | | Restricted stock units granted | | | 641,000 | | | 2.93 | | | Restricted stock units cancelled | | | (111,750) | | | 3.58 | | | Restricted stock units vested | | | (227,292) | | | 3.56 | | | Unvested balance at December 31, 2016 | | | 10,094,095 | | $ | 2.49 | |
|
| Schedule of Warrant Activities |
The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies:
| | | | | | | Total weighted | | Weighted average | | | | | | | Weighted average | | average intrinsic | | remaining contractual | | | | | Number of shares | | exercise price | | value | | life (years) | | | Outstanding as of December 31, 2015 | | | 569,835 | | $ | 6.31 | | $ | 120,700 | | | 1.84 | | | Granted | | | 1,880,000 | | | 3.00 | | | - | | | 5.65 | | | Expired | | | (161,382) | | | 6.30 | | | - | | | - | | | Exercised (*) | | | (25,000) | | | 1.37 | | | 33,250 | | | - | | | Outstanding as of December 31, 2016 | | | 2,263,453 | | $ | 3.62 | | $ | 79,800 | | | 4.74 | | | Exercisable as of December 31, 2016 | | | 483,453 | | $ | 5.88 | | $ | 79,800 | | | 2.13 | | (*) - cashless
|
| Schedule of Fair Value of Separate Accounts by Major Category of Investment |
On July 15, 2015 and on October 31, 2016, the following grants of 500,000 warrants each were made to Dr. Rosenwald and Mr. Weiss for their services to the Company: | | | | | | | | | | | Exercise | | | | | 2015 | | Warrant Shares | | Risk Free Rate | | Volatilty | | Life | | price | | Fair Value | | | Mustang | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.147 | | $ | 135 | | | Checkpoint | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.129 | | $ | 118 | | | Avenue | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.146 | | $ | 134 | | | CNDO SO | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 1.190 | | $ | 1,091 | | | Helocyte | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.097 | | $ | 89 | | | JMC | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.650 | | $ | 596 | | | Escala | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.071 | | $ | 65 | | | 2016 | | | | | | | | | | | | | | | | | | | | | Cellvation | | | 1,000,000 | | | 2.86 | % | | 70 | % | | 9 | | $ | 0.024 | | $ | 18,075 | |
|
| Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions |
The fair value of options granted in 2016 was estimated using the following assumptions:
| | | For the year ended | | | | | December 31, 2016 | | | Risk-free interest rate | | | 1.14% - 2.25 | % | | Expected dividend yield | | | - | | | Expected term in years | | | 5.05 - 6.95 | | | Expected volatility | | | 96.89% - 105.48 | % |
|
| Schedule of Share-based Compensation, Restricted Stock Award Activity |
| | | | | | | | | | | | | Fair Value | | | | | RSU Grant | | Vesting Term | | Vested | | Forfeited | | Unvested | | per Share | | | President | | | 1,500,000 | | | 4 | | | 250,000 | | | (1,250,000) | | | - | | $ | 0.650 | | | Sales Operations Staff | | | 450,000 | | | 4 | | | 116,666 | | | - | | | 333,334 | | $ | 0.650 | | | | | | 1,950,000 | | | | | | 366,666 | | | (1,250,000) | | | 333,334 | | | | |
|